Corcept Therapeutics Incorporated

NASDAQ:CORT

Biotechnology

Healthcare
$67.79 -2.34%

-$1.96 today

Market cap
$7.42B
Beta
0.50
P/E (TTM)
178.2
EPS (TTM)
$0.46
52W Low $28.66High $91.00

Volume 0.74M

Average 1.41M

CORT Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Corcept Therapeutics IncorporatedNASDAQ: CORT

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue grows, but more slowly than its trailing trend

Q2 FY2026 cost of revenue of $4.06M rose 18.3% year over year, behind the +20.8% change in trailing-twelve-month cost of revenue. Sequentially, it rose 40.9% from the prior quarter. Over 3 fiscal years it compounded at +34.1% a year.

Context

  • Cost of revenue amounted to 1.7% of revenue in FY2025, unchanged from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +18.3% toward the trailing-twelve-month pace of +20.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$4.06M+40.9% QoQ
Last fiscal yearDec 2025
$12.98M+19.3% YoY
LTMJun 2026
$14.09M+20.8% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.3%——
1 year+19.3%——
3-year CAGR+34.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
12.98M USD
Year-over-year change
+19.3%
4-year CAGR
+25.2%

Cost of Revenue vs competitors

How CORT compares with its peers on the latest reported figures

  • CORT's LTM Jun 2026 cost of revenue of $14.09M is the highest of the 3 companies compared; the peer median is $62K.
  • Its year-over-year change of +20.8% is the lowest of 2, against a peer median of +24.0%.
  • Cost of revenue amounts to 1.7% of revenue for CORT.
CORT Competitors Peer median
Cost of Revenue for CORT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$14.09M +20.8%+34.1%1.7%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$124K +24.0%——
SPRBSpruce Biosciences, Inc.LTM Mar 2026$0 ———
Peer median (excluding CORT) $62K+24.0%——

Competitors are the stored peer set for CORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue365.98M401.86M482.38M675.04M761.41M
Cost of Revenue5.28M5.39M6.48M10.88M12.98M
Gross Profit360.7M396.47M475.89M664.16M748.43M
Gross Margin98.6%98.7%98.7%98.4%98.3%
Research & Development113.86M130.99M184.35M246.89M254.91M
Selling, General & Admin122.36M152.85M184.26M280.32M448.73M
Operating Expenses236.22M283.84M368.61M527.21M703.63M
Depreciation & Amortization3.07M3.45M2.36M1.34M1.89M
EBITDA127.95M119.64M126.92M162.83M68.35M
EBITDA Margin35.0%29.8%26.3%24.1%9.0%
Operating Income124.48M112.63M107.28M136.95M44.8M
Operating Margin34.0%28.0%22.2%20.3%5.9%
Interest Income529K3.56M17.28M24.54M21.67M
Interest Expense00000
Other Income / Expenses529K3.56M17.28M24.54M21.67M
Income Before Tax125.01M116.19M124.56M161.49M66.46M
Pre-Tax Margin34.2%28.9%25.8%23.9%8.7%
Income Tax Expense12.49M14.77M18.42M20.28M(33.19M)
Net Income112.51M101.42M106.14M139.73M99.65M
Net Margin30.7%25.2%22.0%20.7%13.1%
EPS (Basic)0.970.951.021.350.95
EPS (Diluted)0.890.870.941.230.82
Weighted Avg Shares115.65M106.79M103.56M103.23M103.86M
Weighted Avg Shares (Diluted)125.96M115.97M111.74M113.48M119.99M

Corcept Therapeutics Incorporated

NASDAQ:CORT

Intrinsic Alpha fair value

Locked

Current Price

$67.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.